medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2025-15-7-13medalphabet-4444Research ArticleСтатьиПрофилактическое лечение мигрени: практические рекомендации Международного общества головной боли (IHS)Preventive Pharmacological Treatment of Migraine: International Headache Society (IHS) Global Practice Recommendationshttps://orcid.org/0000-0001-9978-4180ФилатоваЕ. Г.FilatovaE. G.

Филатова Елена Глебовна, д.м.н., проф., проф. кафедры нервных болезней ИПО; врач-невролог

Москва

Filatova Elena G., DM Sci (habil.), professor at Dept of Neurology, Institute of Professional Education; neurologist

Moscow 

https://orcid.org/0000-0001-9828-2509АмелинА. В.AmelinA. V.

Амелин Александр Витальевич, д.м.н., проф., проф. кафедры неврологии

Санкт-Петербург

Amelin Alexander V., DM Sci (habil.), professor at Dept of Neurology

St. Petersburg 

https://orcid.org/0000-0001-9600-5540ЛатышеваН. В.LatyshevaN. V.

Латышева Нина Владимировна, д.м.н., доцент, проф. кафедры нервных болезней ИПО; врач-невролог

Москва

Latysheva Nina V., DM Sci (habil.), professor at Dept of Neurology, Institute of Professional Education; neurologist

Moscow 

ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России (Сеченовский университет); Клиника головной боли и вегетативных расстройств им. академика Александра ВейнаРоссияI. M. Sechenov First Moscow State Medical University (Sechenov University); Alexander Vein Headache ClinicRussian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова» Минздрава РоссииРоссияPavlov First State Medical University of St. Petersburg (Pavlov University)Russian Federation202526072025015«Неврология и психиатрия» (2)713Copyright © Филатова Е.Г., Амелин А.В., Латышева Н.В., 20252025Филатова Е.Г., Амелин А.В., Латышева Н.В.Filatova E.G., Amelin A.V., Latysheva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4444

В статье представлен адаптированный перевод практических рекомендаций по профилактическому лечению мигрени, выпущенных в конце 2024 г. Международным обществом головной боли (IHS). Документ содержит 16 наиболее важных практических вопросов по профилактике мигрени, ответы на которые получены из клинических рекомендаций разных стран, метаанализов и рандомизированных клинических исследований (РКИ).

Основной целью практических рекомендаций по профилактике мигрени является оптимизация использования лекарственных средств для эффективного контроля за часто возникающей и хронической мигренью и повышения качества медицинской помощи у наибольшего числа пациентов в странах с различным экономическим уровнем развития. В Российской Федерации (РФ) доступны таргетные профилактические препараты (анти-CGRP моноклональные антитела, гепанты) и ботулотоксин типа А, а также большинство классических таблетированных средств. Таким образом, в нашей стране возможно осуществлять профилактическое лечение мигрени любого, в том числе оптимального уровня. В комментариях этой статьи авторы российской версии стремились адаптировать ответы на наиболее важные вопросы к клинической практике в РФ.

The article presents an adapted translation of the practice recommendations for the preventive treatment of migraine, released in late 2024 by the International Headache Society (IHS). The document contains 16 of the most important practical questions on migraine prevention, the answers to which are obtained from clinical guidelines from different countries, meta-analyses and randomized clinical trials (RCTs).The main objective of these practice recommendations for migraine prevention is to optimize the use of drugs for effective control of frequent and chronic migraine and to improve the quality of medical care for the greatest number of patients in countries with different levels of economic development. In the Russian Federation (RF), both targeted prophylactic drugs (anti-CGRP monoclonal antibodies, gepants), botulinum toxin type A and most classical oral medications are available. Thus, in our country it is possible to offer preventive treatment of migraine of any level, including the optimal one. In the comments to this article, the authors of the Russian version sought to adapt the answers to the most important questions to clinical practice in the Russian Federation.

мигреньлечение мигренипрофилактика мигренирекомендации по профилактике мигрениmigrainemigraine treatmentmigraine preventionmigraine prevention guidelinesReferencesPuledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S, Burstein R, Liebler E, Cipriani A, Chu MK, Cocores A, Dodd-Glover F, Ekizoğlu E, Garcia-Azorin D, Göbel CH, Goicochea MT, Hassan A, Hirata K, Hoffmann J, Jenkins B, Kamm K, Lee MJ, Ling YH, Lisicki M, Martinelli D, Monteith TS, Ornello R, Özge A, Peres MFP, Pozo-Rosich P, Romanenko V, Schwedt TJ, Souza MNP, Takizawa T, Terwindt GM, Thuraiaiyah J, Togha M, Vandenbussche N, Wang SJ, Yu S, Tassorelli C. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia. 2024 Sep; 44 (9): 3331024241269735.Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S, Burstein R, Liebler E, Cipriani A, Chu MK, Cocores A, Dodd-Glover F, Ekizoğlu E, Garcia-Azorin D, Göbel CH, Goicochea MT, Hassan A, Hirata K, Hoffmann J, Jenkins B, Kamm K, Lee MJ, Ling YH, Lisicki M, Martinelli D, Monteith TS, Ornello R, Özge A, Peres MFP, Pozo-Rosich P, Romanenko V, Schwedt TJ, Souza MNP, Takizawa T, Terwindt GM, Thuraiaiyah J, Togha M, Vandenbussche N, Wang SJ, Yu S, Tassorelli C. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia. 2024 Sep; 44 (9): 3331024241269735.Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference. Neuropsychiatr Dis Treat. 2010; 6: 17–28.Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference. Neuropsychiatr Dis Treat. 2010; 6: 17–28.Couch JR, Amitriptyline Versus Placebo Study G. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011; 51: 33–51.Couch JR, Amitriptyline Versus Placebo Study G. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011; 51: 33–51.Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S; Italian Migraine Registry study group. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Neurology. 2023; 101 (11): 482–488.Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S; Italian Migraine Registry study group. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Neurology. 2023; 101 (11): 482–488.Hepp Z, Bloudek LM and Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014; 20: 22–33.Hepp Z, Bloudek LM and Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014; 20: 22–33.Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, Reuter U. Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. Front Neurol. 2020; 11: 417.Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, Reuter U. Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. Front Neurol. 2020; 11: 417.Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2022; 62 (1): 106–108.Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2022; 62 (1): 106–108.Alsaadi T, Suliman R, Santos V, Al Qaisi I, Carmina P, Aldaher B, Haddad S, Bader Y. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study. Neurol Ther. 2024; 13 (2): 465–473.Alsaadi T, Suliman R, Santos V, Al Qaisi I, Carmina P, Aldaher B, Haddad S, Bader Y. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study. Neurol Ther. 2024; 13 (2): 465–473.Pascual J, Leira R and Láinez JM. Combined therapy for migraine prevention? Clinical experience with a betablocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003; 23: 961–962.Pascual J, Leira R and Láinez JM. Combined therapy for migraine prevention? Clinical experience with a betablocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003; 23: 961–962.Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007; 115 (2): 81–3.Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007; 115 (2): 81–3.Krymchantowski AV, da Cunha Jevoux C and Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain. 2012; 13: 53–59.Krymchantowski AV, da Cunha Jevoux C and Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain. 2012; 13: 53–59.Barbanti P, Aurilia C, Torelli P, Egeo G, d'Onofrio F, Finocchi C, Carnevale A, Viticchi G, Russo M, Quintana S, Orlando B, Fiorentini G, Messina R, Bartolini M, Pistoia F, Filippi M, Bonassi S, Cevoli S, Mannocci A; Italian Migraine Registry (I-GRAINE) study group. Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study. J Neurol. 2025; 272 (2): 170.Barbanti P, Aurilia C, Torelli P, Egeo G, d'Onofrio F, Finocchi C, Carnevale A, Viticchi G, Russo M, Quintana S, Orlando B, Fiorentini G, Messina R, Bartolini M, Pistoia F, Filippi M, Bonassi S, Cevoli S, Mannocci A; Italian Migraine Registry (I-GRAINE) study group. Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study. J Neurol. 2025; 272 (2): 170.Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, Grazzi L, Usai S, D'Amico D. Predictors of 12-Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache. 2017; 57 (1): 60–70.Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, Grazzi L, Usai S, D'Amico D. Predictors of 12-Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache. 2017; 57 (1): 60–70.Wöber C, Wöber-Bingöl C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991; 11 (6): 251–6.Wöber C, Wöber-Bingöl C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991; 11 (6): 251–6.Diener HC, Dodick DW, Aurora SK. et al. Onabotulinumtoxina for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804–814.Diener HC, Dodick DW, Aurora SK. et al. Onabotulinumtoxina for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804–814.Goadsby PJ, Silberstein SD, Yeung PP. et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020; 95: e2487–e2499.Goadsby PJ, Silberstein SD, Yeung PP. et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020; 95: e2487–e2499.Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 402: 775–785.Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 402: 775–785.Overeem LH, Peikert A, Hofacker MD. et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia. 2022; 42: 291–301.Overeem LH, Peikert A, Hofacker MD. et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia. 2022; 42: 291–301.Patier Ruiz I, Sanchez-Rubio Ferrandez J, Carcamo Fonfria A. et al. Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series. Eur Neurol 2022; 85:132–135.Patier Ruiz I, Sanchez-Rubio Ferrandez J, Carcamo Fonfria A. et al. Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series. Eur Neurol 2022; 85:132–135.Straube A, Broessner G, Gaul C. et al. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study. J Headache Pain. 2023 May 23; 24 (1): 59.Straube A, Broessner G, Gaul C. et al. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study. J Headache Pain. 2023 May 23; 24 (1): 59.Scuteri D, Tonin P, Nicotera P. et al. Pooled analysis of realworld evidence supports anti-CGRP mAbs and onabotulinumtoxin А combined trial in chronic migraine. Toxins. 2022; 14: 529.Scuteri D, Tonin P, Nicotera P. et al. Pooled analysis of realworld evidence supports anti-CGRP mAbs and onabotulinumtoxin А combined trial in chronic migraine. Toxins. 2022; 14: 529.Abu-Arafeh I, Razak S, Sivaraman B. et al. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010; 52: 1088–1097.Abu-Arafeh I, Razak S, Sivaraman B. et al. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010; 52: 1088–1097.Martin PR. Behavioral management of migraine headache triggers: learning to cope with triggers. Curr Pain Headache Rep. 2010; 14: 221–227.Martin PR. Behavioral management of migraine headache triggers: learning to cope with triggers. Curr Pain Headache Rep. 2010; 14: 221–227.Göbel H. Non pharmaceutical treatments for migraine. Rev Neurol (Paris) 2005;161:685–686.Göbel H. Non pharmaceutical treatments for migraine. Rev Neurol (Paris) 2005;161:685–686.Pérez-Muñoz A, Buse DC and Andrasik F. Behavioral interventions for migraine. Neurol Clin. 2019; 37: 789–813.Pérez-Muñoz A, Buse DC and Andrasik F. Behavioral interventions for migraine. Neurol Clin. 2019; 37: 789–813.Moisset X, Pereira B, Ciampi de Andrade D. et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2020; 21: 142.Moisset X, Pereira B, Ciampi de Andrade D. et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2020; 21: 142.Sarchielli P, Mancini ML and Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging. 2006; 23: 461–489.Sarchielli P, Mancini ML and Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging. 2006; 23: 461–489.Diener H, Bussone G, Oene JV. et al. Topiramate reduces headache days in chronic migraine: a randomized, doubleblind, placebo-controlled study. Cephalalgia. 2007; 27: 814–823.Diener H, Bussone G, Oene JV. et al. Topiramate reduces headache days in chronic migraine: a randomized, doubleblind, placebo-controlled study. Cephalalgia. 2007; 27: 814–823.

The authors declare that there are no conflicts of interest present.